➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Johnson and Johnson
Express Scripts
Mallinckrodt
Merck

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Zamicastat

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Zamicastat?

Zamicastat is an investigational drug.

There have been 4 clinical trials for Zamicastat. The most recent clinical trial was a Phase 1 trial, which was initiated on June 6th 2019.

The most common disease conditions in clinical trials are Hypertension, Familial Primary Pulmonary Hypertension, and Cardiovascular Diseases. The leading clinical trial sponsors are Bial - Portela C S.A., Covance, and [disabled in preview].

There are eight US patents protecting this investigational drug and ninety international patents.

Recent Clinical Trials for Zamicastat
TitleSponsorPhase
Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAHBial - Portela C S.A.Phase 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058Bial - Portela C S.A.Phase 1
Effect of BIA 5 1058 on Cardiac RepolarizationCovancePhase 1

See all Zamicastat clinical trials

Clinical Trial Summary for Zamicastat

Top disease conditions for Zamicastat
Top clinical trial sponsors for Zamicastat

See all Zamicastat clinical trials

US Patents for Zamicastat

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Zamicastat   Start Trial Process for preparing 1,3-dihydroimidazole-2-thione derivatives Bial-Portela & CA, S.A. (S. Mamede do Coronado, PT)   Start Trial
Zamicastat   Start Trial 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury Bial-Portela & CA, S.A. (S. Mamede do Coronado, PT)   Start Trial
Zamicastat   Start Trial Processes for preparing medicaments for the treatment of cardiovascular diseases and intermediates for use therein Bial-Portela & CA, S.A. (S. Mamede do Coronado, PT)   Start Trial
Zamicastat   Start Trial 1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase Bial-Portela & CA, S.A. (S. Mamede Do Coronado, PT)   Start Trial
Zamicastat   Start Trial Crystalline forms and processes for their preparation Bial-Portela & CA, S.A. (S. Mamede Do Coronado, PT)   Start Trial
Zamicastat   Start Trial Process for preparing 1, 3-Dihydroimidazole-2-Thione Derivatives Bial-Portela & CA, S.A. (S. Mamede do Coronado, PT)   Start Trial
Zamicastat   Start Trial 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury Bial-Portela & CA, S.A. (S. Mamede do Coronado, PT)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Zamicastat

Drugname Country Document Number Estimated Expiration Related US Patent
Zamicastat European Patent Office 2726454 2031-06-29   Start Trial
Zamicastat Spain 2667099 2031-06-29   Start Trial
Zamicastat Japan 2014520796 2031-06-29   Start Trial
Zamicastat Japan 5981539 2031-06-29   Start Trial
Zamicastat Portugal 2726454 2031-06-29   Start Trial
Zamicastat World Intellectual Property Organization (WIPO) 2013002660 2031-06-29   Start Trial
Zamicastat Australia 2013345494 2032-11-14   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Johnson and Johnson
Express Scripts
Mallinckrodt
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.